Suzhou Shengdiya Biomedicine Co Ltd, a drug maker in SIP, received on May 29 the approval from National Medical Products Administration of China for marketing its new drug Camrelizumab for Injection, a humanized anti-PD-1 monoclonal antibody that binds to the human PD-1 receptor and blocks the PD-1/PD-L1 pathway to restore human body’s anti-tumor immunity.

The proprietary product is applicable to treatment of patients with relapsed and/or refractory classic Hodgkin’s lymphoma who have received at least second-line systemic therapy (including autologous hematopoietic stem cell transplantation).